Navigation Links
Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
Date:5/11/2009

Announces Positive Top Line Results of its Clinical Study of LT-NS001 vs. naproxen and Achievement of Financing Milestone

WALTHAM, Mass., May 11 /PRNewswire/ -- Logical Therapeutics, Inc (Logical), a biotechnology company focused on the development of products that treat diseases associated with inflammation, today announced that Peter A. Lankau has been appointed Chief Executive Officer, and has been elected to the Company's Board of Directors. Mr. Lankau was most recently President and CEO of Endo Pharmaceuticals Inc., a publicly traded specialty pharmaceutical company.

"I am excited to be teaming up with such an experienced group of scientists and investors to develop clinically meaningful and novel products for inflammatory diseases," said Mr. Lankau. "Logical Therapeutics' pipeline includes important medicines for the millions of people who suffer from chronic inflammatory conditions. Logical's lead compound, LT-NS001 will be particularly important for patients whose need for non-steroidal anti-inflammatory treatment is complicated by significant gastrointestinal risks."

Mr. Lankau became President and CEO of Endo Pharmaceuticals in 2005, after having served as President and COO since 2003, and SVP of Commercial Business since 2000. Previously, Mr. Lankau was Vice President, Sales and Marketing at Alpharma, Inc. and held various management positions at Rhone-Poulenc Rorer.

"We are delighted to have Peter join the Logical team and our Board of Directors," said Lutz Giebel, Chairman of Logical Therapeutics, Inc., and the Managing Partner of SV Life Sciences Advisers LLC, a lead investor in Logical, "His experience in leading a growth oriented public company, his execution of numerous business development transactions, and his understanding of the commercially important, and value creating elements of drug development, will help propel Logical toward significant business opportunities
'/>"/>

SOURCE Logical Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
5. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
8. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
9. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
10. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
11. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Eli Lilly and Company (NYSE: LLY ) and Incyte ... June 11 to discuss data from the first two pivotal ... two trials, RA-BEACON and RA-BUILD, will be presented on June ... in Rome, Italy . The ... Time. The live audio webcast can be accessed through a ...
(Date:5/28/2015)... , May 28, 2015  The U.S. Department ... Orbit Medical Inc. and Rehab Medical Inc. to resolve ... with the filing of a whistleblower lawsuit by two ... sales representatives, under the direction of one of Orbit,s ... so that Orbit could obtain payment from Medicare for ...
(Date:5/28/2015)... , May 28, 2015 ... Testing Market - Size, Industry Analysis, Trends, Opportunities, Growth and ... reach $3.6 billion by 2020. The secondary syphilis testing ... 2020. Latin America , ... (LAMEA) market accounted for about 43% revenue share ...
Breaking Medicine Technology:Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 2Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 4Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 2Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 3
... Mich., Sept. 13, 2011 The University of Michigan Health ... clinical alarm and alert data from medical to communications devices, ... Children,s Hospital and Von Voigtlander Women,s Hospital. "Moving ... room to a much larger facility where beds are now ...
... CORTLANDT MANOR, N.Y., Sept. 13, 2011 Polymedco, Inc. ... Health, Inc., for distribution of its market leading automated ... help increase patient compliance rates and aid in the ... of the OC-Auto Micro 80; automated FIT analyzer; and ...
Cached Medicine Technology:New Hospitals to Implement New Communications Technology 2Polymedco, Inc., and Cardinal Health Sign Agreement for Distribution of Oncologic Diagnostic Test Kits to Acute Care Market 2
(Date:5/28/2015)... RI (PRWEB) May 28, 2015 As the ... beach to keep cool. It’s important to make safety a ... is sharing some swimming tips. , According to the Centers ... in the United States, not including boating incidents. Additionally, the ... death for children ages 1 to 4. , Amica ...
(Date:5/28/2015)... Lauderdale, Florida (PRWEB) May 28, 2015 ... Havlicek, and wife Beth, both Genesis Foundation Board of ... Annual John Havlicek Celebrity Fishing Tournament June 4-7. For ... this 4-day event benefitting The Genesis Foundation for children ... the cause. , The 34th John Havlicek Celebrity ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 The CEO ... announced a just launched blog series which provides analysis ... Hosted on the “R. Bruce Dalglish” profile on Blogger.com, ... R. Bruce Dalglish’s corporate experience. , “Throughout my ... workplace cultures have upon the overall success of businesses,” ...
(Date:5/28/2015)... 2015 Nidra Herbal Sleep Supplement features a ... body. A non-addictive supplement, Nidra Herbal Sleep Supplement is more ... will leave users with a real sense of wellbeing the ... Ayurveda, which translates as the “Science or Knowledge of Life”, ... and is a holistic system of knowledge which combines contemplation, ...
(Date:5/28/2015)... 2015 Baptist Medical Center Jacksonville has ... from acute stroke or other neurological conditions. , The ... a few in the country and the first in ... such as brain aneurysms. , “Baptist Health is ... patients who are impacted by stroke,” said Nicole Thomas, ...
Breaking Medicine News(10 mins):Health News:Splash! Amica Shares 6 Swimming Safety Tips 2Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:R. Bruce Dalglish, CEO of Alliance Hospice, Introduces New Blog Series On Positive Corporate Culture 2Health News:Ayurveda Herba Corp’s Revolutionary Herbal Sleep Supplement is Now Available from Amazon.com 2Health News:Baptist Medical Center Jacksonville Adds Dedicated Neuro Emergency Unit 2Health News:Baptist Medical Center Jacksonville Adds Dedicated Neuro Emergency Unit 3
... , HOUSTON , Feb. 8 ... technology are invited to visit the NASA Goes the Distance exhibit ... Expo at the Palmer Event Center. NASA,s exhibit will be open ... 10 a.m. to 6 p.m. Saturday . The exhibit will ...
... MONDAY, Feb. 8 (HealthDay News) -- Decreased handgrip strength in ... say. , In a new study, handgrip strength was measured ... group of 555 participants in the Netherlands. The researchers found ... a greater decline in strength over time, was associated with ...
... New York,s ... , ... February 8, 2010 -- As a proactive measure, New York City and the Environmental Protection ... with the support of personal injury attorneys. As reported by The New York Times ...
... , Feb. 8 Aton Pharma, Inc., a ... Richardson has joined the company as Vice President, Commercial ... Donald A. Fishbein assumes the same role for the ... Holdings LLC, Aton is focused on the development and commercialization ...
... , , , , , ... Feb. 8 /PRNewswire-Asia-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink Sheet: ... botanical products,bio-pharmaceuticals and traditional Chinese medicines ("TCM"), announced today,that it ... fiscal year ended, October 31, 2009 on time. In ...
... ... NuEarth Corporation (Pinksheets: NUEC) (“NuEarth”), a manufacturer and ... that the company’s Laboratory and Research Division “TerraSolv SA” has ... contract representing an additional $1.3 Million laboratory service contract with ...
Cached Medicine News:Health News:NASA Joins Austin Marathon Expo, Inspires Students 2Health News:Handgrip Strength Helps Predict Death Risk in Elderly 2Health News:New York Examines Possible Contamination in Public City Schools 2Health News:Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 3Health News:NuEarth Signs $1.3 Million Laboratory Contract 2Health News:NuEarth Signs $1.3 Million Laboratory Contract 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: